APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine Contract Manufacturing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026

Report ID 17415816043 May 2026195 pages

Choose your research edition.

Industry ResearchHuman Vaccine Contract Manufacturing Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Human Vaccine Contract Manufacturing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Vaccine Contract Manufacturing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Vaccine Contract Manufacturing market include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc. and PRA Health Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Vaccine Contract Manufacturing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Vaccine Contract Manufacturing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Vaccine Contract Manufacturing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Vaccine Contract Manufacturing market.

Human Vaccine Contract Manufacturing Segment by Company

Lonza

Fujifilm Diosynth Biotechnologies U.S.A., Inc.

Ajinomoto Althea, Inc.

Merck KgaA

Cytovance Biologics

Catalent, Inc.

IDT Biologika GmbH

Albany Molecular Research, Inc.

PRA Health Sciences

ICON plc.

Pharmaceutical Product Development, LLC

Cobra Bio

Paragon Bioservices, Inc.

Emergent BioSolutions Inc.

CSL Limited

BioNTech SE

Wuxi Biologics

Samsung Biologics

Boehringer Ingelheim

Novavax, Inc.

Human Vaccine Contract Manufacturing Segment by Type

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Human Vaccine Contract Manufacturing Segment by Application

Downstream

Upstream

Human Vaccine Contract Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Vaccine Contract Manufacturing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Vaccine Contract Manufacturing key companies, revenue, market share, and recent developments.

3. To split the Human Vaccine Contract Manufacturing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Vaccine Contract Manufacturing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Vaccine Contract Manufacturing significant trends, drivers, influence factors in global and regions.

6. To analyze Human Vaccine Contract Manufacturing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine Contract Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Vaccine Contract Manufacturing industry.

Chapter 3: Detailed analysis of Human Vaccine Contract Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Vaccine Contract Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Vaccine Contract Manufacturing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Vaccine Contract Manufacturing Industry Trends Table 2. Human Vaccine Contract Manufacturing Industry Drivers Table 3. Human Vaccine Contract Manufacturing Industry Opportunities and Challenges Table 4. Human Vaccine Contract Manufacturing Industry Restraints Table 5. Global Human Vaccine Contract Manufacturing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Vaccine Contract Manufacturing Revenue Share by Company (2021-2026) Table 7. Global Human Vaccine Contract Manufacturing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Vaccine Contract Manufacturing Key Company Manufacturing Base & Headquarters Table 9. Global Human Vaccine Contract Manufacturing Company, Product Type & Application Table 10. Global Human Vaccine Contract Manufacturing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Vaccine Contract Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Attenuated Table 15. Significant Companies of Inactivated Table 16. Significant Companies of Subunit-based Table 17. Significant Companies of Toxoid-based Table 18. Significant Companies of DNA-based Table 19. Global Human Vaccine Contract Manufacturing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Human Vaccine Contract Manufacturing Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Human Vaccine Contract Manufacturing Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Human Vaccine Contract Manufacturing Sales Value Share by Type (2021-2026) Table 23. Global Human Vaccine Contract Manufacturing Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Downstream Table 25. Significant Companies of Upstream Table 26. Global Human Vaccine Contract Manufacturing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Human Vaccine Contract Manufacturing Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Human Vaccine Contract Manufacturing Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Human Vaccine Contract Manufacturing Sales Value Share by Application (2021-2026) Table 30. Global Human Vaccine Contract Manufacturing Sales Value Share by Application (2027-2032) Table 31. Global Human Vaccine Contract Manufacturing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Human Vaccine Contract Manufacturing Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Human Vaccine Contract Manufacturing Sales Value Share by Region (2021-2026) Table 34. Global Human Vaccine Contract Manufacturing Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Human Vaccine Contract Manufacturing Sales Value Share by Region (2027-2032) Table 36. Global Human Vaccine Contract Manufacturing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human Vaccine Contract Manufacturing Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Human Vaccine Contract Manufacturing Sales Value Market Share by Country (2021-2026) Table 39. Global Human Vaccine Contract Manufacturing Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Human Vaccine Contract Manufacturing Sales Value Market Share by Country (2027-2032) Table 41. Lonza Company Information Table 42. Lonza Business Overview Table 43. Lonza Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Lonza Human Vaccine Contract Manufacturing Product Portfolio Table 45. Lonza Recent Development Table 46. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information Table 47. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview Table 48. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 50. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development Table 51. Ajinomoto Althea, Inc. Company Information Table 52. Ajinomoto Althea, Inc. Business Overview Table 53. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 55. Ajinomoto Althea, Inc. Recent Development Table 56. Merck KgaA Company Information Table 57. Merck KgaA Business Overview Table 58. Merck KgaA Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio Table 60. Merck KgaA Recent Development Table 61. Cytovance Biologics Company Information Table 62. Cytovance Biologics Business Overview Table 63. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 65. Cytovance Biologics Recent Development Table 66. Catalent, Inc. Company Information Table 67. Catalent, Inc. Business Overview Table 68. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 70. Catalent, Inc. Recent Development Table 71. IDT Biologika GmbH Company Information Table 72. IDT Biologika GmbH Business Overview Table 73. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio Table 75. IDT Biologika GmbH Recent Development Table 76. Albany Molecular Research, Inc. Company Information Table 77. Albany Molecular Research, Inc. Business Overview Table 78. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 80. Albany Molecular Research, Inc. Recent Development Table 81. PRA Health Sciences Company Information Table 82. PRA Health Sciences Business Overview Table 83. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio Table 85. PRA Health Sciences Recent Development Table 86. ICON plc. Company Information Table 87. ICON plc. Business Overview Table 88. ICON plc. Human Vaccine Contract Manufacturing Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. ICON plc. Human Vaccine Contract Manufacturing Product Portfolio Table 90. ICON plc. Recent Development Table 91. Pharmaceutical Product Development, LLC Company Information Table 92. Pharmaceutical Product Development, LLC Business Overview Table 93. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio Table 95. Pharmaceutical Product Development, LLC Recent Development Table 96. Cobra Bio Company Information Table 97. Cobra Bio Business Overview Table 98. Cobra Bio Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio Table 100. Cobra Bio Recent Development Table 101. Paragon Bioservices, Inc. Company Information Table 102. Paragon Bioservices, Inc. Business Overview Table 103. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 105. Paragon Bioservices, Inc. Recent Development Table 106. Emergent BioSolutions Inc. Company Information Table 107. Emergent BioSolutions Inc. Business Overview Table 108. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 110. Emergent BioSolutions Inc. Recent Development Table 111. CSL Limited Company Information Table 112. CSL Limited Business Overview Table 113. CSL Limited Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. CSL Limited Human Vaccine Contract Manufacturing Product Portfolio Table 115. CSL Limited Recent Development Table 116. BioNTech SE Company Information Table 117. BioNTech SE Business Overview Table 118. BioNTech SE Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio Table 120. BioNTech SE Recent Development Table 121. Wuxi Biologics Company Information Table 122. Wuxi Biologics Business Overview Table 123. Wuxi Biologics Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 125. Wuxi Biologics Recent Development Table 126. Samsung Biologics Company Information Table 127. Samsung Biologics Business Overview Table 128. Samsung Biologics Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 130. Samsung Biologics Recent Development Table 131. Boehringer Ingelheim Company Information Table 132. Boehringer Ingelheim Business Overview Table 133. Boehringer Ingelheim Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio Table 135. Boehringer Ingelheim Recent Development Table 136. Novavax, Inc. Company Information Table 137. Novavax, Inc. Business Overview Table 138. Novavax, Inc. Human Vaccine Contract Manufacturing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 140. Novavax, Inc. Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Human Vaccine Contract Manufacturing Product Image Figure 2. Global Human Vaccine Contract Manufacturing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Vaccine Contract Manufacturing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Attenuated Image Figure 8. Inactivated Image Figure 9. Subunit-based Image Figure 10. Toxoid-based Image Figure 11. DNA-based Image Figure 12. Global Human Vaccine Contract Manufacturing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Human Vaccine Contract Manufacturing Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Human Vaccine Contract Manufacturing Sales Value Share by Type (2021-2032) Figure 15. Downstream Image Figure 16. Upstream Image Figure 17. Global Human Vaccine Contract Manufacturing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human Vaccine Contract Manufacturing Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human Vaccine Contract Manufacturing Sales Value Share by Application (2021-2032) Figure 20. Global Human Vaccine Contract Manufacturing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Human Vaccine Contract Manufacturing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Human Vaccine Contract Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 23. North America Human Vaccine Contract Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Human Vaccine Contract Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Human Vaccine Contract Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Human Vaccine Contract Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Human Vaccine Contract Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Human Vaccine Contract Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 29. South America Human Vaccine Contract Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Human Vaccine Contract Manufacturing Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Human Vaccine Contract Manufacturing Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based
Applications
  • Downstream
  • Upstream
Companies covered
  • Lonza
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • BioNTech SE
  • Wuxi Biologics
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novavax, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Vaccine Contract Manufacturing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Vaccine Contract Manufacturing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Vaccine Contract Manufacturing Market Dynamics
  1. 2.1 Human Vaccine Contract Manufacturing Industry Trends
  2. 2.2 Human Vaccine Contract Manufacturing Industry Drivers
  3. 2.3 Human Vaccine Contract Manufacturing Industry Opportunities and Challenges
  4. 2.4 Human Vaccine Contract Manufacturing Industry Restraints
3 Human Vaccine Contract Manufacturing Market by Company
  1. 3.1 Global Human Vaccine Contract Manufacturing Company Revenue Ranking in 2025
  2. 3.2 Global Human Vaccine Contract Manufacturing Revenue by Company (2021-2026)
  3. 3.3 Global Human Vaccine Contract Manufacturing Company Ranking (2024-2026)
  4. 3.4 Global Human Vaccine Contract Manufacturing Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Vaccine Contract Manufacturing Company Product Type and Application
  6. 3.6 Global Human Vaccine Contract Manufacturing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Vaccine Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Vaccine Contract Manufacturing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Vaccine Contract Manufacturing Market by Type
  1. 4.1 Human Vaccine Contract Manufacturing Type Introduction
  2. 4.1.1 Attenuated
  3. 4.1.2 Inactivated
  4. 4.1.3 Subunit-based
  5. 4.1.4 Toxoid-based
  6. 4.1.5 DNA-based
  7. 4.2 Global Human Vaccine Contract Manufacturing Sales Value by Type
  8. 4.2.1 Global Human Vaccine Contract Manufacturing Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Vaccine Contract Manufacturing Sales Value by Type (2021-2032)
  10. 4.2.3 Global Human Vaccine Contract Manufacturing Sales Value Share by Type (2021-2032)
5 Human Vaccine Contract Manufacturing Market by Application
  1. 5.1 Human Vaccine Contract Manufacturing Application Introduction
  2. 5.1.1 Downstream
  3. 5.1.2 Upstream
  4. 5.2 Global Human Vaccine Contract Manufacturing Sales Value by Application
  5. 5.2.1 Global Human Vaccine Contract Manufacturing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Vaccine Contract Manufacturing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Human Vaccine Contract Manufacturing Sales Value Share by Application (2021-2032)
6 Human Vaccine Contract Manufacturing Regional Value Analysis
  1. 6.1 Global Human Vaccine Contract Manufacturing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Vaccine Contract Manufacturing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Vaccine Contract Manufacturing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Vaccine Contract Manufacturing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Vaccine Contract Manufacturing Sales Value (2021-2032)
  7. 6.3.2 North America Human Vaccine Contract Manufacturing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Vaccine Contract Manufacturing Sales Value (2021-2032)
  10. 6.4.2 Europe Human Vaccine Contract Manufacturing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Vaccine Contract Manufacturing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Vaccine Contract Manufacturing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Vaccine Contract Manufacturing Sales Value (2021-2032)
  16. 6.6.2 South America Human Vaccine Contract Manufacturing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Vaccine Contract Manufacturing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Vaccine Contract Manufacturing Sales Value Share by Country, 2025 VS 2032
7 Human Vaccine Contract Manufacturing Country-level Value Analysis
  1. 7.1 Global Human Vaccine Contract Manufacturing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Vaccine Contract Manufacturing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Vaccine Contract Manufacturing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Vaccine Contract Manufacturing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Vaccine Contract Manufacturing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Vaccine Contract Manufacturing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Vaccine Contract Manufacturing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Human Vaccine Contract Manufacturing Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  8. 8.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information
  9. 8.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
  10. 8.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio
  12. 8.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
  13. 8.3 Ajinomoto Althea, Inc.
  14. 8.3.1 Ajinomoto Althea, Inc. Company Information
  15. 8.3.2 Ajinomoto Althea, Inc. Business Overview
  16. 8.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  18. 8.3.5 Ajinomoto Althea, Inc. Recent Developments
  19. 8.4 Merck KgaA
  20. 8.4.1 Merck KgaA Company Information
  21. 8.4.2 Merck KgaA Business Overview
  22. 8.4.3 Merck KgaA Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio
  24. 8.4.5 Merck KgaA Recent Developments
  25. 8.5 Cytovance Biologics
  26. 8.5.1 Cytovance Biologics Company Information
  27. 8.5.2 Cytovance Biologics Business Overview
  28. 8.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio
  30. 8.5.5 Cytovance Biologics Recent Developments
  31. 8.6 Catalent, Inc.
  32. 8.6.1 Catalent, Inc. Company Information
  33. 8.6.2 Catalent, Inc. Business Overview
  34. 8.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  36. 8.6.5 Catalent, Inc. Recent Developments
  37. 8.7 IDT Biologika GmbH
  38. 8.7.1 IDT Biologika GmbH Company Information
  39. 8.7.2 IDT Biologika GmbH Business Overview
  40. 8.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio
  42. 8.7.5 IDT Biologika GmbH Recent Developments
  43. 8.8 Albany Molecular Research, Inc.
  44. 8.8.1 Albany Molecular Research, Inc. Company Information
  45. 8.8.2 Albany Molecular Research, Inc. Business Overview
  46. 8.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  48. 8.8.5 Albany Molecular Research, Inc. Recent Developments
  49. 8.9 PRA Health Sciences
  50. 8.9.1 PRA Health Sciences Company Information
  51. 8.9.2 PRA Health Sciences Business Overview
  52. 8.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio
  54. 8.9.5 PRA Health Sciences Recent Developments
  55. 8.10 ICON plc.
  56. 8.10.1 ICON plc. Company Information
  57. 8.10.2 ICON plc. Business Overview
  58. 8.10.3 ICON plc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ICON plc. Human Vaccine Contract Manufacturing Product Portfolio
  60. 8.10.5 ICON plc. Recent Developments
  61. 8.11 Pharmaceutical Product Development, LLC
  62. 8.11.1 Pharmaceutical Product Development, LLC Company Information
  63. 8.11.2 Pharmaceutical Product Development, LLC Business Overview
  64. 8.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio
  66. 8.11.5 Pharmaceutical Product Development, LLC Recent Developments
  67. 8.12 Cobra Bio
  68. 8.12.1 Cobra Bio Company Information
  69. 8.12.2 Cobra Bio Business Overview
  70. 8.12.3 Cobra Bio Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio
  72. 8.12.5 Cobra Bio Recent Developments
  73. 8.13 Paragon Bioservices, Inc.
  74. 8.13.1 Paragon Bioservices, Inc. Company Information
  75. 8.13.2 Paragon Bioservices, Inc. Business Overview
  76. 8.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  78. 8.13.5 Paragon Bioservices, Inc. Recent Developments
  79. 8.14 Emergent BioSolutions Inc.
  80. 8.14.1 Emergent BioSolutions Inc. Company Information
  81. 8.14.2 Emergent BioSolutions Inc. Business Overview
  82. 8.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio
  84. 8.14.5 Emergent BioSolutions Inc. Recent Developments
  85. 8.15 CSL Limited
  86. 8.15.1 CSL Limited Company Information
  87. 8.15.2 CSL Limited Business Overview
  88. 8.15.3 CSL Limited Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CSL Limited Human Vaccine Contract Manufacturing Product Portfolio
  90. 8.15.5 CSL Limited Recent Developments
  91. 8.16 BioNTech SE
  92. 8.16.1 BioNTech SE Company Information
  93. 8.16.2 BioNTech SE Business Overview
  94. 8.16.3 BioNTech SE Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio
  96. 8.16.5 BioNTech SE Recent Developments
  97. 8.17 Wuxi Biologics
  98. 8.17.1 Wuxi Biologics Company Information
  99. 8.17.2 Wuxi Biologics Business Overview
  100. 8.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio
  102. 8.17.5 Wuxi Biologics Recent Developments
  103. 8.18 Samsung Biologics
  104. 8.18.1 Samsung Biologics Company Information
  105. 8.18.2 Samsung Biologics Business Overview
  106. 8.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio
  108. 8.18.5 Samsung Biologics Recent Developments
  109. 8.19 Boehringer Ingelheim
  110. 8.19.1 Boehringer Ingelheim Company Information
  111. 8.19.2 Boehringer Ingelheim Business Overview
  112. 8.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio
  114. 8.19.5 Boehringer Ingelheim Recent Developments
  115. 8.20 Novavax, Inc.
  116. 8.20.1 Novavax, Inc. Company Information
  117. 8.20.2 Novavax, Inc. Business Overview
  118. 8.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  120. 8.20.5 Novavax, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst